Clinical Trial Update: A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing chemotherapy with ramucirumab versus chemotherapy alone in second-line NSCLC after platinum-based first-line therapy; trial completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-12-29